MSC and Exosomes in Cardiovascular Therapy
This article specifically focuses on the emerging role of extracellular vesicles (EVs) derived from Mesenchymal Stem Cells (MSCs) in cardiovascular repair and regeneration.
Focus on Extracellular Vesicles (EVs)
The study highlights that EVs, including exosomes, are the primary mediators of the therapeutic effects of MSCs in the cardiovascular system.
These vesicles deliver bioactive molecules such as microRNAs (miRNAs), proteins, and lipids to target cells.
Specific Mechanism of Action
These EVs can transfer their cargo to damaged cardiac cells, modulating gene expression and repairing tissue damage caused by myocardial infarction (MI) or ischemia.
Challenges and Potential
Although MSC therapy has shown promise, the direct use of MSC-derived EVs provides a cell-free approach that may reduce safety concerns (such as embolism) and simplify production and storage, positioning EVs as a promising future therapy.
Therapeutic Benefits of MSCs and EVs in Cardiovascular Repair
1. Reduction of Ischemia/Reperfusion (I/R) Injury
- EVs help protect myocardial tissue from cell death (apoptosis) occurring after ischemic events and subsequent reperfusion.
2. Promotion of Angiogenesis
- EV cargo promotes the formation of new capillaries and blood vessels in ischemic regions.
- This neovascularization is essential for delivering oxygen and nutrients, supporting tissue repair, and improving cardiac function.
3. Anti-inflammatory and Remodeling Effects
- EVs modulate the inflammatory microenvironment in the heart post-infarction.
- They also help attenuate adverse ventricular remodeling, preventing progressive enlargement and weakening of the heart after a heart attack.
4. Tissue Repair and Regeneration
- EVs contribute to proliferation and migration of cardiac cells or endogenous progenitor cells, supporting myocardial regeneration.
